Delaying Esophageal Cancer Surgery After Neoadjuvant CRT Fails in Trial
Prolonging the time to surgery following neoadjuvant chemoradiotherapy (CRT) for esophageal cancer failed to improve histological complete response rates and may even worsen overall survival (OS), according to results from the randomized NeoRes II study. Among the subset with adenocarcinoma, complete response rates were not significantly better with the prolonged surgical approach (10-12 weeks) compared […]
PD-1 Inhibitor Boosts Survival in Treated Esophageal Cancer
Overall survival (OS) in previously treated esophageal cancer improved significantly with the anti-PD-1 drug tislelizumab compared to chemotherapy, a phase III, randomized trial showed. Patients randomized to tislelizumab had a median OS of 8.6 months as compared with 6.3 months for patients who received chemotherapy alone. A prespecified subgroup analysis of patients from Europe and […]